Genzyme Receives "Complete Response," Warning Letters For Lumizyme
This article was originally published in Pharmaceutical Approvals Monthly
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter
You may also be interested in...
Until approval of the larger 4000 L bioreactor for the Pompe Disease product, EMEA recommends priority access for infants, children and adolescents.
The 2,000L version of Myozyme on track for approval with a post-market confirmatory trial in February; user fee date extended while FDA reviews REMS submission.
Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.